Clinical Trial Search

Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…

Primary: The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage Fluid After Segmental Allergen Challenge, Before and After Mepolizumab…

Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants

Primary: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils — -84.4; 27.7 Percent change in MFI

Primary: Change From Baseline in Total Subepithelial Eosinophils at the End of Week 78 (End of Treatment) — -5.807; -5.890; 1.555; -5.626 cells/mm^2

Primary: Fold Increase in ASM Proliferation Following Incubation With Eosinophils. — 2; 2 Fold increase in ASM cell proliferation — p=<0.05

Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change

Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53

Primary: Change From Baseline in 24-hour Cough Frequency at 14 Weeks — 17.0; 17.0; 12.6; 10.6 Coughs/hour — p=0.99

Primary: Airway Resistance at 5 Hz (R5) at Baseline (Pre-mepolizumab Initiation) — 0.51; 0.39; 0.43 kPa/L/s

Primary: Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups — 0.6; -7.5 perecentage of eos per…

Primary: The Ability of AVTX-002 to Improve Asthma Control in Subjects With Poorly Controlled Non-eosinophilic Asthma (NEA) Based on the Percentage of Patients Who Experience…

Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage

Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…

Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants

Primary: Rate of Clinically Significant Exacerbations of Asthma — 0.45; 1.31 Exacerbations per year — p=<0.001

Primary: Asthma Exacerbations During 52 Weeks Preceding Treatment Initiation (as Assessed at Baseline) and at the 24th and 52nd Week of the Treatment — 3; 0; 0 number of asthma…

Primary: Lung Function FEV1 — 84.9; 59.9 % of predicted — p=0.001

Primary: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control — 7…

Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52

Primary: Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of Treatment — 0.52; 0.41 events — p=0.194

Primary: FeNO — 14.3; 34.3; 36.0; 49 parts per billion — p=<0.1

Primary: Change in Exhaled Nitric Oxide From Baseline to Week 12 — -11.0 parts per billion (ppb) — p=0.005

Primary: Number of Participants Who Maintained an Absolute Peripheral Blood Neutrophil Count >=1500/µL — 20; 12 Number of participants

Primary: Change in Number of Exacerbations of the Participants — 2.77; 1.32 Change in number of courses of oral c

Primary: Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 24 — -7.9; -15.6 Scores on a scale — p=<0.001

Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…

Primary: Change From Baseline at Week 16 in Sinonasal Outcome Test -22 (SNOT-22) Score — -14.09; -4.37 points

Primary: Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 32 — -1.45 Scores on a scale — p=<0.001

Primary: Annualized Rate of Clinically Significant Exacerbations Over 52 Weeks — 0.57; 0.49 Exacerbation per participant per year — p=0.079